Article Text

Download PDFPDF
Angiotensin receptor blockers reduce erythrocyte sedimentation rate levels in patients with rheumatoid arthritis
  1. M E Perry1,
  2. M M Chee1,
  3. W R Ferrell1,
  4. J C Lockhart2,
  5. R D Sturrock1
  1. 1
    Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, Scotland, UK
  2. 2
    School of Engineering & Science, University of Paisley, Paisley, Scotland UK
  1. Dr Martin Edward Perry, Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow G31 2ER, Scotland, UK; martinperry{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The proinflammatory properties of angiotensin II have been well described.1 Indeed, the angiotensin 1 receptor (AT1 receptor) is present and upregulated in the synovium of patients with rheumatoid arthritis (RA).2 Two separate studies, have confirmed the therapeutic effect of angiotensin converting enzyme inhibitors (ACEi)3 and angiotensin receptor blockers (ARB)4 on joint inflammation in both mouse and rat. ACEi may differ from ARB as the former tend to be non-specific in their anti-inflammatory effect.

To assess the effect of ACEi and ARB on human C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels, a retrospective analysis was performed …

View Full Text


  • Competing interests: None.